French biotech Abivax reported positive results from two Phase 3 trials of its oral treatment obefazimod for moderate to severe ulcerative colitis. The pooled clinical remission rate was 16.4% above placebo after 8 weeks of treatment. Both trials met primary endpoints, though one dose group in a trial faced challenges. The drug showed a favorable safety profile with no new issues. Abivax plans regulatory submissions in 2026 and continues maintenance and Crohn’s disease studies.